Form 4: Guardant Health CFO Michael Brian Bell Reports Stock Option and Restricted Stock Unit Awards
SEC Form 4 Filing
Michael Brian Bell, CFO of Guardant Health, reports the acquisition of stock options and restricted stock units.
Summary
- On March 12, 2025, Michael Brian Bell, the Chief Financial Officer of Guardant Health, Inc., was granted stock options and restricted stock units.
- The stock option award is for 33,498 shares with an exercise price of $43.10.
- 33% of the stock options vest on April 1, 2026, and the remaining 67% vest in equal monthly installments over the following two years.
- The restricted stock unit award is for 22,332 shares.
- 33% of the restricted stock units vest on April 1, 2026, and the remaining 67% vest in equal quarterly installments over the following two years.
- The options expire on March 12, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and restricted stock units is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.
Positives
- The granting of stock options and restricted stock units to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
- Companies like Illumina, Roche, and Exact Sciences also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules described are typical for these types of awards.
Stakeholder Impact
- Shareholders may view the granting of stock options and restricted stock units as a positive sign, aligning management's interests with their own.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of the stock option and restricted stock unit awards. |
| 03/13/2025 | Date of signature on the Form 4 filing. |
| 04/01/2026 | First vesting date for 33% of both the stock options and restricted stock units. |
| 03/12/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.